Halozyme Therapeutics, Inc. (HALO): Price and Financial Metrics

Halozyme Therapeutics, Inc. (HALO): $56.47

1.80 (+3.29%)

POWR Rating

Component Grades













Add HALO to Watchlist
Sign Up

Industry: Biotech



in industry


  • Quality is the dimension where HALO ranks best; there it ranks ahead of 86.66% of US stocks.
  • HALO's strongest trending metric is Quality; it's been moving down over the last 178 days.
  • HALO ranks lowest in Momentum; there it ranks in the 4th percentile.

HALO Stock Summary

  • HALOZYME THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 92.89% of US listed stocks.
  • The ratio of debt to operating expenses for HALOZYME THERAPEUTICS INC is higher than it is for about 87.55% of US stocks.
  • HALO's price/sales ratio is 12.66; that's higher than the P/S ratio of 91.32% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to HALOZYME THERAPEUTICS INC are ITGR, BIGC, CGNX, NTCT, and PRGS.
  • HALO's SEC filings can be seen here. And to visit HALOZYME THERAPEUTICS INC's official web site, go to www.halozyme.com.

HALO Valuation Summary

  • HALO's price/sales ratio is 12.7; this is 164.58% higher than that of the median Healthcare stock.
  • Over the past 228 months, HALO's price/earnings ratio has gone up 152.4.

Below are key valuation metrics over time for HALO.

Stock Date P/S P/B P/E EV/EBIT
HALO 2022-11-25 12.7 76.2 35.0 35.4
HALO 2022-11-23 12.7 75.8 34.8 35.2
HALO 2022-11-22 12.5 74.8 34.3 34.8
HALO 2022-11-21 12.4 74.3 34.1 34.6
HALO 2022-11-18 12.3 73.8 33.9 34.4
HALO 2022-11-17 12.3 73.6 33.8 34.3

HALO Growth Metrics

    Its 2 year revenue growth rate is now at 186.85%.
  • Its year over year revenue growth rate is now at 42.35%.
  • The 3 year price growth rate now stands at 124.18%.
HALO's revenue has moved up $384,631,000 over the prior 33 months.

The table below shows HALO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 580.623 240.173 211.197
2022-06-30 487.477 292.277 366.15
2022-03-31 471.567 288.941 434.923
2021-12-31 443.31 299.44 402.71
2021-09-30 463.01 267.844 409.104
2021-06-30 412.496 152.189 228.724

HALO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HALO has a Quality Grade of C, ranking ahead of 73.97% of graded US stocks.
  • HALO's asset turnover comes in at 0.493 -- ranking 84th of 682 Pharmaceutical Products stocks.
  • ARAV, XOMA, and MGNX are the stocks whose asset turnover ratios are most correlated with HALO.

The table below shows HALO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.493 0.814 0.250
2021-06-30 0.533 0.823 0.255
2021-03-31 0.510 0.832 0.224
2020-12-31 0.504 0.838 0.220
2020-09-30 0.378 0.831 0.053
2020-06-30 0.369 0.720 -0.037

HALO Price Target

For more insight on analysts targets of HALO, see our HALO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $52.82 Average Broker Recommendation 1.62 (Moderate Buy)

HALO Stock Price Chart Interactive Chart >

Price chart for HALO

HALO Price/Volume Stats

Current price $56.47 52-week high $57.67
Prev. close $54.67 52-week low $31.36
Day low $54.86 Volume 1,780,700
Day high $57.67 Avg. volume 1,129,724
50-day MA $46.01 Dividend yield N/A
200-day MA $43.19 Market Cap 7.64B

Halozyme Therapeutics, Inc. (HALO) Company Bio

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company was founded in 1998 and is based in San Diego, California.

HALO Latest News Stream

Event/Time News Detail
Loading, please wait...

HALO Latest Social Stream

Loading social stream, please wait...

View Full HALO Social Stream

Latest HALO News From Around the Web

Below are the latest news stories about HALOZYME THERAPEUTICS INC that investors may wish to consider to help them evaluate HALO as an investment opportunity.

Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why

Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.

Yahoo | November 25, 2022

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Yahoo | November 25, 2022

GILD vs. HALO: Which Stock Is the Better Value Option?

GILD vs. HALO: Which Stock Is the Better Value Option?

Yahoo | November 22, 2022

HALO Stock: Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming Growth

Halozyme's under-the-skin technology helps deliver some of the biggest moneymaking injections, fueling booming growth and prospects for much more. HALO stock is surging.

Yahoo | November 15, 2022

Should You Hold Halozyme Therapeutics (HALO)?

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned 3.23%, Advisor Class fund APDSX posted a return of 3.27%, and Institutional Class fund APHSX returned 3.27%, compared to a […]

Yahoo | November 15, 2022

Read More 'HALO' Stories Here

HALO Price Returns

1-mo 17.06%
3-mo 38.64%
6-mo 23.65%
1-year 69.68%
3-year 191.23%
5-year 202.46%
YTD 40.44%
2021 -5.85%
2020 140.89%
2019 21.19%
2018 -27.79%
2017 105.06%

Continue Researching HALO

Want to see what other sources are saying about Halozyme Therapeutics Inc's financials and stock price? Try the links below:

Halozyme Therapeutics Inc (HALO) Stock Price | Nasdaq
Halozyme Therapeutics Inc (HALO) Stock Quote, History and News - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6916 seconds.